An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.

Autor: Morgans, Alicia K.1 (AUTHOR) aliciak_morgans@dfci.harvard.edu, Hutson, Thomas2 (AUTHOR), Guan, Alice Kai Dan3 (AUTHOR), Garcia, David3 (AUTHOR) David.Garcia@Eversana.com, Zhou, Anna3 (AUTHOR), Drea, Edward4 (AUTHOR), Vogelzang, Nicholas J.5 (AUTHOR)
Zdroj: BMC Health Services Research. 7/14/2022, Vol. 22 Issue 1, p1-10. 10p. 4 Charts, 4 Graphs.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje